| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6200984 | Ophthalmology | 2015 | 10 Pages |
Abstract
Intravitreal ranibizumab therapy for the treatment of DME confers considerable patient (human)Â value gain. It also accrues financial value to patients, public and private insurers, and society.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Gary C. MD, MBA, Melissa M. MD, MBA, Adam PhD, Yamina PhD,